Review article · 2026 · Open access

The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases

Takashi K. Satoh, Mark Mellett, Lars Einar French

Allergology International, 75(3), 366–379 · Published 20 February 2026 · DOI 10.1016/j.alit.2026.01.006

Open full textCite this paper

In brief

“The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases” is a 2026 review article by Takashi K. Satoh and 2 co-authors, published in Allergology International. OpenAlex counts 8 citations as of 18 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Allergology International.

Citations
8
Most cited in
2026 (8)
Field-weighted impact
3.34
References
157
Authors
3

Abstract

The interleukin-36 (IL-36) cytokine family is an important regulator of inflammatory responses at epithelial barrier surfaces, with particularly prominent roles in skin immunity and inflammatory disease. As members of the IL-1 superfamily, IL-36 cytokines include three agonists (IL-36α, IL-36β, and IL-36γ) and two antagonists (IL-36Ra and IL-38), which signal through a shared heterodimeric receptor complex to activate MyD88-dependent pathways, including NF-κB and MAPK, and induce pro-inflammatory cytokines, chemokines, and antimicrobial peptides. A defining feature of IL-36 biology is its dependence on proteolytic activation, whereby neutrophil- and pathogen-derived proteases convert low-activity precursors into highly active cytokines, enabling rapid amplification of inflammation and linking epithelial stress to neutrophil recruitment. The clinical relevance of IL-36 signaling was established by the identification of loss-of-function mutations in IL36RN, encoding IL-36Ra, in generalized pustular psoriasis (GPP), a severe and potentially life-threatening neutrophilic dermatosis. These discoveries validated IL-36R as a therapeutic target and culminated in regulatory approval of IL-36R blockade for the treatment of GPP flares. Beyond GPP, accumulating evidence implicates IL-36 in inflammatory processes across multiple organ systems. This review summarizes IL-36 molecular biology, receptor trafficking and signaling, and protease-dependent activation, and discusses roles in barrier immunity and host defense. We also synthesize evidence for pathogenic contributions of IL-36 across inflammatory skin diseases and extra-cutaneous disorders, and highlight emerging therapeutic strategies, biomarkers of response, and future clinical directions.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Satoh, T. K., Mellett, M., & French, L. E. (2026). The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases. Allergology International, 75(3), 366–379. https://doi.org/10.1016/j.alit.2026.01.006

MLA 9

Satoh, Takashi K., et al. “The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases.” Allergology International, vol. 75, no. 3, 2026, pp. 366–379. https://doi.org/10.1016/j.alit.2026.01.006.

Chicago

Satoh, Takashi K., Mark Mellett, and Lars Einar French. 2026. “The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases.” Allergology International 75 (3): 366–379. https://doi.org/10.1016/j.alit.2026.01.006.

Harvard

Satoh, T. K., Mellett, M. and French, L. E. (2026) ‘The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases’, Allergology International, 75(3), pp. 366–379. doi:10.1016/j.alit.2026.01.006.

IEEE

T. K. Satoh, M. Mellett, and L. E. French, “The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases,” Allergology International, vol. 75, no. 3, pp. 366–379, 2026, doi: 10.1016/j.alit.2026.01.006.

BibTeX

@article{satoh2026cytokine,
  title     = {{The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases}},
  author    = {Satoh, Takashi K. and Mellett, Mark and French, Lars Einar},
  journal   = {Allergology International},
  year      = {2026},
  volume    = {75},
  number    = {3},
  pages     = {366--379},
  doi       = {10.1016/j.alit.2026.01.006},
  url       = {https://doi.org/10.1016/j.alit.2026.01.006}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis

  • IL-36 receptor
  • IL36RN
  • generalized pustular psoriasis
  • MyD88 signaling
  • NF-κB
  • mitogen-activated protein kinase
  • skin immunity
  • inflammatory skin diseases

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Satoh, T. K., Mellett, M., & French, L. E. (2026). The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases. Allergology International, 75(3), 366–379. https://doi.org/10.1016/j.alit.2026.01.006

How many times has this paper been cited?

8 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Allergology International: sign in and open the full text from this page.

Who wrote this paper?

Takashi K. Satoh, Mark Mellett, Lars Einar French.

What is the DOI of this paper?

10.1016/j.alit.2026.01.006, permanently at https://doi.org/10.1016/j.alit.2026.01.006. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.